Sprint Bioscience: Announces rights issue - Redeye

Redeye comments on Sprint Bioscience announcing a rights issue. The capital raise aligns with our expectations but comes at a lower subscription price than we estimated earlier this year. We will adjust our estimates and valuation once the company communicates the rights issue’s outcome in mid-November.

Länk till analysen i sin helhet: https://www.redeye.se/research/856127/sprint-bioscience-announces-rights-issue?utm_source=finwire&utm_medium=RSS